News

Orpheus has licensced the PR1P technology from Boston Children’s Hospital, where it was originally develped and characterized, to facilitate the preclinical and clinical development of this exciting therapeutic. In pursuit of this, Orpheus has completed a pre-IND meeting with the FDA for the treatment of retinopathy of prematurity with PR1P, delineating a clinical and regulatory development path.